BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28073588)

  • 1. Overexpression of cytochrome P450 2A6 in adrenocortical carcinoma.
    Murtha TD; Brown TC; Rubinstein JC; Haglund F; Juhlin CC; Larsson C; Korah R; Carling T
    Surgery; 2017 Jun; 161(6):1667-1674. PubMed ID: 28073588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of cytochrome P450 4B1: An early event in adrenocortical tumorigenesis.
    Murtha TD; Korah R; Carling T
    Surgery; 2017 Jan; 161(1):257-263. PubMed ID: 27865598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression.
    Wang T; Subramanian C; Blagg BSJ; Cohen MS
    Surgery; 2020 Jan; 167(1):233-240. PubMed ID: 31561992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.
    Ronchi CL; Sbiera S; Volante M; Steinhauer S; Scott-Wild V; Altieri B; Kroiss M; Bala M; Papotti M; Deutschbein T; Terzolo M; Fassnacht M; Allolio B
    PLoS One; 2014; 9(8):e105855. PubMed ID: 25144458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
    Brown TC; Nicolson NG; Korah R; Carling T
    J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy.
    Buishand FO; Liu-Chittenden Y; Fan Y; Tirosh A; Gara SK; Patel D; Meerzaman D; Kebebew E
    Surgery; 2020 Jan; 167(1):224-232. PubMed ID: 31522749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma.
    Liang R; Weigand I; Lippert J; Kircher S; Altieri B; Steinhauer S; Hantel C; Rost S; Rosenwald A; Kroiss M; Fassnacht M; Sbiera S; Ronchi CL
    Front Endocrinol (Lausanne); 2020; 11():219. PubMed ID: 32373071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
    Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
    Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
    Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
    J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
    Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
    Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines.
    Germano A; Rapa I; Volante M; Lo Buono N; Carturan S; Berruti A; Terzolo M; Papotti M
    Mol Cell Endocrinol; 2014 Jan; 382(1):1-7. PubMed ID: 24018612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma.
    Özata DM; Caramuta S; Velázquez-Fernández D; Akçakaya P; Xie H; Höög A; Zedenius J; Bäckdahl M; Larsson C; Lui WO
    Endocr Relat Cancer; 2011 Oct; 18(6):643-55. PubMed ID: 21859927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
    Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
    Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis.
    Cheng JY; Brown TC; Murtha TD; Stenman A; Juhlin CC; Larsson C; Healy JM; Prasad ML; Knoefel WT; Krieg A; Scholl UI; Korah R; Carling T
    BMC Cancer; 2017 Mar; 17(1):164. PubMed ID: 28249601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
    Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
    Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
    Robitaille CN; Rivest P; Sanderson JT
    Toxicol Sci; 2015 Jan; 143(1):126-35. PubMed ID: 25324206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas.
    Nolé P; Duijndam B; Stenman A; Juhlin CC; Kozyra M; Larsson C; Ingelman-Sundberg M; Johansson I
    PLoS One; 2016; 11(9):e0162379. PubMed ID: 27598485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
    Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
    Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
    Phan LM; Fuentes-Mattei E; Wu W; Velazquez-Torres G; Sircar K; Wood CG; Hai T; Jimenez C; Cote GJ; Ozsari L; Hofmann MC; Zheng S; Verhaak R; Pagliaro L; Cortez MA; Lee MH; Yeung SC; Habra MA
    Cancer Res; 2015 Oct; 75(19):4131-42. PubMed ID: 26282167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular markers and targeted therapies for adrenocortical carcinoma.
    Xu Y; Qi Y; Zhu Y; Ning G; Huang Y
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.